Centogene N.V. (Nasdaq: CNTG), the essential life science partner
for data-driven answers in rare and neurodegenerative diseases,
today announced the expansion of MOx, the Company’s multiomic
diagnostic portfolio, now incorporating cutting-edge transcriptomic
analysis.
CENTOGENE’s MOx 2.0 is a single-step multiomic solution that
combines DNA sequencing, biochemical testing, and now RNA
sequencing to provide physicians with the most comprehensive
testing capability.
Transcriptomics examines the transcripts to reveal
mutation-specific RNA patterns, differences in gene expression, and
how cells and tissues respond to environmental or physiological
changes. Using RNA sequencing, a more complete picture of disease
biology and response to drugs can be established.
“Rare and neurodegenerative diseases often present complex
diagnostic challenges, requiring a deeper understanding of the
genetic and molecular factors at play,” said Prof. Peter Bauer,
Chief Medical & Genomic Officer at CENTOGENE. “We understand
that genomics alone is not enough, so we have developed what we
believe to be one of the most comprehensive and innovative
multiomic offerings on the market that helps patients receive an
accurate diagnosis. Leveraging transcriptomics, the CENTOGENE
Biodatabank, and CentoCard®, MOx 2.0 enables us to translate
variants of unknown significance into a precise diagnosis and
revolutionize precision medicine for rare and neurodegenerative
disease patients.”
MOx 2.0 – A Paradigm Shift in Real-World Patient
Diagnostics
CENTOGENE’s enhanced multiomic portfolio consists of three
seamlessly integrated key updates:
Highest Diagnostic Yield With
Transcriptomics
- By integrating RNA sequencing, a
more complete picture of disease biology can be established,
capturing over an estimated 60% of tested patients with suspected
genetic disorders, compared to 40-50% with standard Whole Exome and
Genome Sequencing
Simplified Logistics
- Leveraging CentoCard®, CENTOGENE’s
state-of-the-art filter card technology for extracting high-quality
extraction of DNA, RNA, enzymes, and metabolites from dried blood
spots, sample collection and shipping has been streamlined –
ensuring accessible multiomic testing for patients worldwide
Unparalleled Insights
- Delivering best-in-class medical
reporting based on bioinformatics, artificial intelligence, and
medical expert-based analysis of the CENTOGENE Biodatabank with
over 800,000 patients represented from over 120 highly diverse
countries, as well as more than 70 million unique variants
About CentoGenome® MOx 2.0
CentoGenome® MOx 2.0 is designed using CENTOGENE’s core Whole
Genome Sequencing to cover more than 7,000 rare diseases, including
over 1,400 inherited metabolic disorders. Now including RNA
analysis for splicing variants, as well as confirmatory testing via
biomarker measurement and enzyme activity analysis, CentoGenome®
MOx 2.0 provides enhanced clinical coverage. CentoGenome® includes
detection of repeat expansions linked to neurological disorders,
copy number variations associated with spinal muscular atrophy, as
well as complex disease-causing variants associated with Gaucher
disease and susceptibility to GBA1-related Parkinson's disease.
About CentoXome® MOx 2.0
CentoXome® MOx 2.0 is built on the foundation of CENTOGENE’s
Whole Exome Sequencing and leverages RNA sequencing and biochemical
testing to evaluate variant exonic regions as well as splicing
regions – establishing a clear understanding of disease-causing
variants on multi-molecular layers.
To find out more about MOx 2.0 and CENTOGENE’s complete
multiomic portfolio, visit: https://link.centogene.com/mox
About CENTOGENE
CENTOGENE’s mission is to provide data-driven, life-changing
answers to patients, physicians, and pharma companies for rare and
neurodegenerative diseases. We integrate multiomic technologies
with the CENTOGENE Biodatabank – providing dimensional analysis to
guide the next generation of precision medicine. Our unique
approach enables rapid and reliable diagnosis for patients,
supports a more precise physician understanding of disease states,
and accelerates and de-risks targeted pharma drug discovery,
development, and commercialization.
Since our founding in 2006, CENTOGENE has been offering rapid
and reliable diagnosis – building a network of approximately 30,000
active physicians. Our ISO, CAP, and CLIA certified multiomic
reference laboratories in Germany utilize Phenomic, Genomic,
Transcriptomic, Epigenomic, Proteomic, and Metabolomic datasets.
This data is captured in our CENTOGENE Biodatabank, with over
800,000 patients represented from over 120 highly diverse
countries, over 70% of whom are of non-European descent. To date,
the CENTOGENE Biodatabank has contributed to generating novel
insights for more than 285 peer-reviewed publications.
By translating our data and expertise into tangible insights, we
have supported over 50 collaborations with pharma partners.
Together, we accelerate and de-risk drug discovery, development,
and commercialization in target and drug screening, clinical
development, market access and expansion, as well as offering
CENTOGENE Biodata Licenses and Insight Reports to enable a world
healed of all rare and neurodegenerative diseases.
To discover more about our products, pipeline, and
patient-driven purpose, visit www.centogene.com and follow us on
LinkedIn.
Forward-Looking Statements
This press release contains “forward-looking statements” within
the meaning of the U.S. federal securities laws. Statements
contained herein that are not clearly historical in nature are
forward-looking, and the words “anticipate,” “believe,”
“continues,” “expect,” “estimate,” “intend,” “project,” “plan,” “is
designed to,” “potential,” “predict,” “objective” and similar
expressions and future or conditional verbs such as “will,”
“would,” “should,” “could,” “might,” “can,” and “may,” or the
negative of these are generally intended to identify
forward-looking statements. Such forward-looking statements involve
known and unknown risks, uncertainties, and other important factors
that may cause CENTOGENE’s actual results, performance, or
achievements to be materially different from any future results,
performance, or achievements expressed or implied by the forward-
looking statements. Such risks and uncertainties include, among
others, negative economic and geopolitical conditions and
instability and volatility in the worldwide financial markets,
possible changes in current and proposed legislation, regulations
and governmental policies, pressures from increasing competition
and consolidation in our industry, the expense and uncertainty of
regulatory approval, including from the U.S. Food and Drug
Administration, our reliance on third parties and collaboration
partners, including our ability to manage growth, execute our
business strategy and enter into new client relationships, our
dependency on the rare disease industry, our ability to manage
international expansion, our reliance on key personnel, our
reliance on intellectual property protection, fluctuations of our
operating results due to the effect of exchange rates, our ability
to streamline cash usage, our continued ongoing compliance with
covenants linked to financial instruments, our requirement for
additional financing, and our ability to continue as a going
concern, or other factors. For further information on the risks and
uncertainties that could cause actual results to differ from those
expressed in these forward-looking statements, as well as risks
relating to CENTOGENE’s business in general, see CENTOGENE’s risk
factors set forth in CENTOGENE’s Form 20-F filed on May 16, 2023,
with the Securities and Exchange Commission (the “SEC”) and
subsequent filings with the SEC. Any forward-looking statements
contained in this press release speak only as of the date hereof,
and CENTOGENE specifically disclaims any obligation to update any
forward-looking statement, whether as a result of new information,
future events, or otherwise.
CONTACT
CENTOGENE
Melissa HallCorporate Communications Press@centogene.com
Lennart StreibelInvestor Relations
IR@centogene.com
Centogene NV (NASDAQ:CNTG)
Gráfica de Acción Histórica
De Abr 2024 a May 2024
Centogene NV (NASDAQ:CNTG)
Gráfica de Acción Histórica
De May 2023 a May 2024